Werewolf Therapeutics Key Executives
This section highlights Werewolf Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Werewolf Therapeutics
(Showing 0 of )
Werewolf Therapeutics Earnings
This section highlights Werewolf Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
$0.86
Stock Price
$38.45M
Market Cap
46
Employees
Cambridge, MA
Location
Financial Statements
Access annual & quarterly financial statements for Werewolf Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $1.89M | $19.94M | $16.40M | $- | $- |
| Cost of Revenue | $- | $38.91M | $2.51M | $735.00K | $777.00K |
| Gross Profit | $1.89M | $-18.96M | $13.89M | $-735.00K | $-777.00K |
| Gross Profit Ratio | 100.00% | -95.09% | 84.70% | - | - |
| Research and Development Expenses | $56.43M | $41.78M | $53.76M | $35.27M | $16.64M |
| General and Administrative Expenses | $19.05M | $18.67M | $18.70M | $14.82M | $5.76M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $19.05M | $18.67M | $18.70M | $14.82M | $5.76M |
| Other Expenses | $- | $- | $2.25M | $104.00K | $7.26M |
| Operating Expenses | $75.48M | $60.45M | $72.46M | $50.09M | $22.40M |
| Cost and Expenses | $75.48M | $60.45M | $72.46M | $50.09M | $22.40M |
| Interest Income | $6.67M | $7.42M | $1.91M | $104.00K | $101.00K |
| Interest Expense | $4.66M | $3.14M | $- | $- | $- |
| Depreciation and Amortization | $1.81M | $1.76M | $2.51M | $735.00K | $777.00K |
| EBITDA | $-64.05M | $-32.47M | $-51.30M | $-49.25M | $-14.26M |
| EBITDA Ratio | -3397.61% | -162.79% | -312.79% | - | - |
| Operating Income | $-73.59M | $-40.50M | $-56.06M | $-50.09M | $-22.40M |
| Operating Income Ratio | -3904.19% | -203.09% | -341.78% | - | - |
| Total Other Income Expenses Net | $3.08M | $3.13M | $2.25M | $104.00K | $7.36M |
| Income Before Tax | $-70.52M | $-37.37M | $-53.81M | $-49.98M | $-15.04M |
| Income Before Tax Ratio | -3740.85% | -187.37% | -328.09% | - | - |
| Income Tax Expense | $- | $- | $-2.25M | $-216.00K | $-101.00K |
| Net Income | $-70.52M | $-37.37M | $-51.56M | $-49.77M | $-14.94M |
| Net Income Ratio | -3740.85% | -187.37% | -314.40% | - | - |
| EPS | $-1.63 | $-1.05 | $-1.79 | $-1.82 | $-0.52 |
| EPS Diluted | $-1.61 | $-1.05 | $-1.79 | $-1.82 | $-0.52 |
| Weighted Average Shares Outstanding | 43.33M | 35.65M | 28.86M | 27.31M | 28.66M |
| Weighted Average Shares Outstanding Diluted | 43.86M | 35.65M | 28.86M | 27.31M | 28.66M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $1.14M | $742.00K | $1.50M | $5.90M | $8.08M | $4.46M | $7.28M | $4.97M | $4.15M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $454.00K | $464.00K | $460.00K | $445.00K | $773.00K | $- | $558.00K | $708.00K | $13.89M | $481.00K | $59.00K | $239.00K | $232.00K | $205.00K | $- | $- | $- | $- |
| Gross Profit | $- | $- | $689.00K | $278.00K | $1.04M | $5.45M | $7.31M | $4.46M | $6.72M | $4.26M | $-9.74M | $-481.00K | $-59.00K | $-239.00K | $-232.00K | $-205.00K | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 60.28% | 37.47% | 69.35% | 92.45% | 90.43% | 100.00% | 92.34% | 85.75% | -234.79% | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $15.73M | $12.53M | $15.27M | $12.91M | $9.65M | $10.84M | $9.58M | $11.71M | $15.86M | $13.07M | $13.89M | $10.95M | $13.40M | $9.79M | $7.26M | $4.82M | $5.29M | $4.81M | $3.78M | $2.76M |
| General and Administrative Expenses | $4.62M | $4.60M | $4.83M | $5.00M | $4.81M | $4.31M | $4.57M | $4.98M | $4.60M | $4.44M | $5.23M | $4.42M | $4.48M | $4.01M | $3.69M | $2.63M | $2.11M | $1.24M | $1.28M | $1.13M |
| Selling and Marketing Expenses | $- | $- | $-454.00K | $-464.00K | $-460.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.62M | $4.60M | $4.38M | $4.53M | $4.35M | $4.31M | $4.57M | $4.98M | $4.60M | $4.44M | $5.23M | $4.42M | $4.48M | $4.01M | $3.69M | $2.63M | $2.11M | $1.24M | $1.28M | $1.13M |
| Other Expenses | $- | $- | $1.61M | $-1.00K | $-6.00K | $966.00K | $-25.00K | $- | $1.25M | $3.00K | $281.00K | $- | $15.00K | $- | $-16.00K | $-16.00K | $-38.00K | $- | $7.30M | $- |
| Operating Expenses | $20.35M | $17.12M | $19.65M | $17.44M | $14.00M | $15.15M | $14.15M | $16.69M | $20.46M | $17.51M | $19.12M | $15.37M | $17.88M | $13.79M | $10.96M | $7.45M | $7.39M | $6.05M | $5.07M | $3.89M |
| Cost and Expenses | $20.35M | $17.12M | $20.10M | $17.90M | $14.46M | $15.15M | $14.15M | $16.69M | $20.46M | $17.51M | $19.12M | $15.37M | $17.88M | $13.79M | $10.96M | $7.45M | $7.39M | $6.05M | $5.07M | $3.89M |
| Interest Income | $1.31M | $1.60M | $1.79M | $1.97M | $2.20M | $1.87M | $994.00K | $1.52M | $1.18M | $593.00K | $97.00K | $23.00K | $15.00K | $37.00K | $51.00K | $33.00K | $10.00K | $- | $24.00K | $67.00K |
| Interest Expense | $1.27M | $1.24M | $1.14M | $1.00M | $1.24M | $900.00K | $955.00K | $172.00K | $- | $593.00K | $97.00K | $23.00K | $- | $37.00K | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $442.00K | $454.00K | $454.00K | $464.00K | $460.00K | $445.00K | $773.00K | $425.00K | $558.00K | $708.00K | $763.00K | $481.00K | $59.00K | $239.00K | $232.00K | $205.00K | $44.00K | $41.00K | $42.00K | $23.00K |
| EBITDA | $-18.69M | $-16.67M | $-15.65M | $-14.73M | $-10.30M | $-8.81M | $-4.33M | $-11.38M | $-12.76M | $-12.13M | $-14.79M | $-15.27M | $-17.81M | $-13.73M | $-10.89M | $-7.41M | $-7.35M | $-6.01M | $-5.02M | $-3.87M |
| EBITDA Ratio | - | - | -1369.47% | -1984.64% | -686.48% | -149.33% | -53.52% | -255.04% | -175.23% | -244.16% | -356.49% | - | - | - | - | - | - | - | - | - |
| Operating Income | $-20.35M | $-17.12M | $-18.96M | $-17.16M | $-12.96M | $-9.25M | $-6.07M | $-12.22M | $-13.18M | $-12.54M | $-14.97M | $-15.37M | $-17.88M | $-13.79M | $-10.96M | $-7.45M | $-7.39M | $-6.05M | $-5.07M | $-3.89M |
| Operating Income Ratio | - | - | -1658.79% | -2312.94% | -863.56% | -156.88% | -75.08% | -273.81% | -180.96% | -252.29% | -360.95% | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $-52.00K | $451.00K | $1.71M | $969.00K | $959.00K | $966.00K | $969.00K | $241.00K | $1.25M | $596.00K | $378.00K | $23.00K | $15.00K | $37.00K | $35.00K | $17.00K | $-10.00K | $-15.00K | $7.32M | $67.00K |
| Income Before Tax | $-20.40M | $-16.67M | $-17.25M | $-16.19M | $-12.00M | $-8.29M | $-5.10M | $-11.98M | $-11.93M | $-11.94M | $-14.59M | $-15.34M | $-17.87M | $-13.76M | $-10.92M | $-7.43M | $-7.40M | $-6.07M | $2.26M | $-3.83M |
| Income Before Tax Ratio | - | - | -1509.10% | -2182.35% | -799.67% | -140.50% | -63.09% | -268.41% | -163.81% | -240.30% | -351.83% | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $- | $- | $- | $-1 | $2.10M | $-445.00K | $-994.00K | $- | $-1.25M | $-596.00K | $-378.00K | $-23.00K | $-48.00K | $-172.00K | $-51.00K | $-33.00K | $-28.00K | $- | $-24.00K | $- |
| Net Income | $-20.40M | $-16.67M | $-17.25M | $-16.19M | $-12.00M | $-8.29M | $-5.10M | $-11.98M | $-10.68M | $-11.35M | $-14.22M | $-15.32M | $-17.87M | $-13.76M | $-10.92M | $-7.43M | $-7.40M | $-6.07M | $2.26M | $-3.83M |
| Net Income Ratio | - | - | -1509.10% | -2182.35% | -799.67% | -140.50% | -63.09% | -268.41% | -146.66% | -228.31% | -342.72% | - | - | - | - | - | - | - | - | - |
| EPS | $-0.46 | $-0.38 | $-0.40 | $-0.39 | $-0.33 | $-0.23 | $-0.14 | $-0.34 | $-0.35 | $-0.38 | $-0.52 | $-0.56 | $-0.66 | $-0.51 | $-0.62 | $-0.28 | $-0.83 | $-0.68 | $0.25 | $-0.43 |
| EPS Diluted | $-0.46 | $-0.38 | $-0.40 | $-0.39 | $-0.33 | $-0.23 | $-0.14 | $-0.34 | $-0.35 | $-0.38 | $-0.52 | $-0.56 | $-0.66 | $-0.51 | $-0.62 | $-0.28 | $-0.83 | $-0.68 | $0.25 | $-0.43 |
| Weighted Average Shares Outstanding | 44.48M | 43.70M | 43.52M | 41.61M | 36.57M | 35.65M | 35.56M | 34.78M | 30.73M | 29.76M | 27.52M | 27.39M | 27.27M | 27.19M | 17.75M | 26.29M | 8.97M | 8.97M | 8.97M | 8.97M |
| Weighted Average Shares Outstanding Diluted | 44.48M | 43.70M | 43.52M | 41.61M | 36.57M | 35.65M | 35.56M | 34.78M | 30.73M | 29.76M | 27.52M | 27.39M | 27.27M | 27.19M | 17.75M | 26.29M | 8.97M | 8.97M | 8.97M | 8.97M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $112.22M | $134.34M | $129.31M | $157.53M | $92.57M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $112.22M | $134.34M | $129.31M | $157.53M | $92.57M |
| Net Receivables | $- | $1.35M | $6.93M | $- | $- |
| Inventory | $- | $- | $2 | $- | $- |
| Other Current Assets | $851.00K | $2.68M | $3.96M | $7.07M | $688.00K |
| Total Current Assets | $113.07M | $138.37M | $140.20M | $161.07M | $92.91M |
| Property Plant Equipment Net | $12.32M | $14.85M | $17.45M | $16.32M | $3.12M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $1.21M | $1.21M | $207.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.54M | $21.62M | $1.38M | $649.00K | $155.00K |
| Total Non-Current Assets | $13.86M | $36.46M | $20.05M | $18.18M | $3.48M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $126.93M | $174.83M | $160.25M | $179.25M | $96.40M |
| Account Payables | $3.04M | $1.34M | $1.22M | $2.04M | $1.02M |
| Short Term Debt | $1.56M | $8.28M | $4.17M | $2.14M | $677.00K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $907.00K | $6.53M | $- | $- |
| Other Current Liabilities | $10.59M | $8.86M | $12.07M | $7.69M | $3.59M |
| Total Current Liabilities | $15.18M | $19.38M | $23.99M | $11.87M | $5.28M |
| Long Term Debt | $9.44M | $43.65M | $25.20M | $29.18M | $1.86M |
| Deferred Revenue Non-Current | $- | $433.00K | $1.13M | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $28.92M | $- | $-12.41M | $-14.59M | $141.11M |
| Total Non-Current Liabilities | $38.36M | $44.08M | $13.92M | $14.59M | $142.98M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $53.54M | $63.46M | $37.91M | $26.46M | $148.26M |
| Preferred Stock | $- | $- | $- | $179.25M | $141.08M |
| Common Stock | $5.00K | $4.00K | $3.00K | $2.00K | $2.00K |
| Retained Earnings | $-414.59M | $-344.07M | $-306.70M | $-252.90M | $-51.87M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $-179.25M | $-141.08M |
| Other Total Stockholders Equity | $487.97M | $455.44M | $429.04M | $405.68M | $2.00K |
| Total Stockholders Equity | $73.39M | $111.37M | $122.34M | $152.79M | $-51.86M |
| Total Equity | $73.39M | $111.37M | $122.34M | $152.79M | $-51.86M |
| Total Liabilities and Stockholders Equity | $126.93M | $174.83M | $160.25M | $179.25M | $96.40M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $126.93M | $174.83M | $160.25M | $179.25M | $96.40M |
| Total Investments | $- | $21.02M | $1.21M | $1.21M | $207.00K |
| Total Debt | $10.99M | $51.92M | $14.68M | $15.66M | $2.54M |
| Net Debt | $-101.22M | $-82.42M | $-114.63M | $-141.87M | $-90.03M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $111.00M | $122.83M | $135.30M | $139.19M | $134.34M | $130.06M | $137.45M | $147.87M | $129.31M | $140.45M | $145.71M | $143.71M | $157.53M | $170.44M | $183.23M | $84.60M | $92.57M | $-17.90M |
| Short Term Investments | $- | $- | $- | $268.69M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $35.79M |
| Cash and Short Term Investments | $111.00M | $122.83M | $135.30M | $139.19M | $134.34M | $130.06M | $137.45M | $147.87M | $129.31M | $140.45M | $145.71M | $143.71M | $157.53M | $170.44M | $183.23M | $84.60M | $92.57M | $17.90M |
| Net Receivables | $- | $464.00K | $545.00K | $775.00K | $1.35M | $5.91M | $6.93M | $6.25M | $6.93M | $4.30M | $2.22M | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $1 | $- | $-8.99M | $208.00K | $- | $2 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $2.07M | $2.54M | $2.94M | $2.32M | $2.68M | $3.29M | $3.02M | $2.44M | $3.96M | $13.67M | $6.23M | $1.73M | $7.07M | $7.93M | $6.25M | $526.00K | $344.00K | $- |
| Total Current Assets | $113.07M | $125.83M | $138.79M | $142.28M | $138.37M | $130.06M | $147.40M | $156.56M | $140.20M | $151.59M | $154.16M | $145.44M | $161.07M | $174.40M | $186.36M | $84.86M | $92.91M | $17.90M |
| Property Plant Equipment Net | $12.32M | $12.94M | $13.44M | $14.04M | $14.85M | $15.59M | $16.17M | $16.83M | $17.45M | $17.77M | $18.10M | $17.34M | $16.32M | $2.75M | $2.82M | $3.00M | $3.12M | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $1.21M | $21.03M | $21.02M | $21.02M | $21.02M | $- | $1.21M | $1.21M | $1.21M | $1.21M | $1.21M | $1.21M | $1.21M | $298.00K | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.54M | $1.26M | $265.00K | $248.00K | $594.00K | $516.00K | $652.00K | $21.68M | $1.38M | $1.85M | $1.85M | $642.00K | $649.00K | $11.00K | $27.00K | $1.27M | $362.00K | $-17.90M |
| Total Non-Current Assets | $13.86M | $14.20M | $14.91M | $35.32M | $36.46M | $37.13M | $37.84M | $38.51M | $20.05M | $20.84M | $21.16M | $19.20M | $18.18M | $3.97M | $4.06M | $4.57M | $3.48M | $-17.90M |
| Other Assets | $- | $- | $1 | $- | $1 | $9.20M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $126.93M | $140.04M | $153.70M | $177.60M | $174.83M | $176.39M | $185.24M | $195.07M | $160.25M | $172.42M | $175.33M | $164.63M | $179.25M | $178.38M | $190.42M | $89.44M | $96.40M | $- |
| Account Payables | $3.04M | $1.24M | $1.47M | $1.59M | $1.34M | $1.39M | $1.49M | $2.11M | $1.22M | $1.39M | $2.59M | $1.38M | $2.04M | $1.46M | $3.19M | $1.80M | $1.02M | $- |
| Short Term Debt | $1.56M | $1.32M | $1.27M | $12.90M | $8.28M | $3.27M | $3.94M | $2.15M | $4.17M | $4.04M | $3.74M | $2.92M | $2.14M | $1.49M | $1.44M | $1.40M | $677.00K | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $502.00K | $907.00K | $2.40M | $1.61M | $4.15M | $6.53M | $10.46M | $11.82M | $- | $- | $- | $- | $2.89M | $- | $- |
| Other Current Liabilities | $10.59M | $9.90M | $8.70M | $6.21M | $8.86M | $7.97M | $7.97M | $13.32M | $12.07M | $11.91M | $12.22M | $6.73M | $7.69M | $4.83M | $2.73M | $2.21M | $3.59M | $- |
| Total Current Liabilities | $15.18M | $12.46M | $11.44M | $21.21M | $19.38M | $2.40M | $15.01M | $21.72M | $23.99M | $27.80M | $30.37M | $11.03M | $11.87M | $7.78M | $7.37M | $5.41M | $5.28M | $- |
| Long Term Debt | $35.53M | $35.46M | $35.40M | $38.37M | $43.65M | $48.92M | $62.55M | $51.11M | $25.20M | $26.29M | $27.35M | $28.57M | $29.18M | $2.59M | $2.98M | $3.37M | $1.86M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $431.00K | $433.00K | $588.00K | $783.00K | $1.17M | $1.13M | $343.00K | $1.25M | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $10.19M | $10.56M | $10.76M | $-783.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $2.83M | $2.73M | $2.84M | $- | $- | $588.00K | $-11.71M | $- | $-12.41M | $-12.95M | $-13.48M | $-14.29M | $-14.59M | $-1.30M | $-1.49M | $234.41M | $141.11M | $- |
| Total Non-Current Liabilities | $38.36M | $38.19M | $38.24M | $38.80M | $44.08M | $49.50M | $51.63M | $52.27M | $13.92M | $13.68M | $15.12M | $14.29M | $14.59M | $1.30M | $1.49M | $237.78M | $142.98M | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $-49.50M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $53.54M | $50.66M | $49.69M | $60.01M | $63.46M | $2.40M | $66.64M | $74.00M | $37.91M | $41.48M | $45.49M | $25.31M | $26.46M | $9.07M | $8.86M | $243.19M | $148.26M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $178.38M | $190.42M | $118.77M | $141.08M | $34.07M |
| Common Stock | $5.00K | $4.00K | $4.00K | $4.00K | $4.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $- |
| Retained Earnings | $-414.59M | $-394.19M | $-377.51M | $-360.27M | $-344.07M | $-332.07M | $-323.79M | $-318.69M | $-306.70M | $-294.77M | $-282.83M | $-268.24M | $-252.90M | $-235.03M | $-221.27M | $-153.76M | $-51.87M | $- |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $111.37M | $- | $- | $0 | $- | $- | $- | $- | $0 | $- | $-178.38M | $-190.42M | $-354.86M | $- | $-24.30M |
| Other Total Stockholders Equity | $487.97M | $483.56M | $481.53M | $477.85M | $455.44M | $444.51M | $442.38M | $439.76M | $429.04M | $425.72M | $412.67M | $407.55M | $405.68M | $404.33M | $402.82M | $472.20M | $-141.08M | $- |
| Total Stockholders Equity | $73.39M | $89.38M | $104.02M | $117.59M | $111.37M | $112.44M | $118.60M | $121.07M | $122.34M | $130.95M | $129.84M | $139.32M | $152.79M | $169.30M | $181.56M | $-153.75M | $-51.86M | $9.77M |
| Total Equity | $73.39M | $89.38M | $104.02M | $117.59M | $111.37M | $112.44M | $118.60M | $121.07M | $122.34M | $130.95M | $129.84M | $139.32M | $152.79M | $169.30M | $181.56M | $-153.75M | $-51.86M | $9.77M |
| Total Liabilities and Stockholders Equity | $126.93M | $140.04M | $153.70M | $177.60M | $174.83M | $176.39M | $185.24M | $195.07M | $160.25M | $172.42M | $175.33M | $164.63M | $179.25M | $178.38M | $190.42M | $89.44M | $96.40M | $9.77M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $126.93M | $140.04M | $153.70M | $177.60M | $174.83M | $176.39M | $185.24M | $195.07M | $160.25M | $172.42M | $175.33M | $164.63M | $179.25M | $178.38M | $190.42M | $89.44M | $96.40M | $9.77M |
| Total Investments | $- | $1.22M | $1.21M | $21.03M | $21.02M | $21.02M | $21.02M | $- | $1.21M | $1.21M | $1.21M | $1.21M | $1.21M | $1.21M | $1.21M | $298.00K | $- | $35.79M |
| Total Debt | $37.09M | $36.78M | $36.68M | $51.27M | $51.92M | $52.19M | $52.82M | $53.25M | $14.68M | $15.16M | $15.55M | $15.74M | $15.66M | $2.04M | $2.21M | $2.38M | $2.54M | $- |
| Net Debt | $-73.91M | $-86.05M | $-98.63M | $-87.92M | $-82.42M | $-77.87M | $-84.64M | $-94.62M | $-114.63M | $-125.29M | $-130.17M | $-127.97M | $-141.87M | $-168.40M | $-181.02M | $-82.22M | $-90.03M | $17.90M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-70.52M | $-37.37M | $-53.81M | $-49.98M | $-15.04M |
| Depreciation and Amortization | $1.81M | $1.76M | $1.10M | $216.00K | $150.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-7.30M |
| Stock Based Compensation | $8.83M | $8.01M | $7.40M | $4.09M | $632.00K |
| Change in Working Capital | $2.53M | $-5.89M | $2.54M | $2.28M | $2.31M |
| Accounts Receivables | $- | $5.58M | $-6.93M | $- | $- |
| Inventory | $- | $- | $6.93M | $- | $- |
| Accounts Payables | $3.46M | $-4.33M | $-883.00K | $1.01M | $388.00K |
| Other Working Capital | $-929.00K | $-7.14M | $3.42M | $1.27M | $1.92M |
| Other Non Cash Items | $1.16M | $878.00K | $2.17M | $519.00K | $627.00K |
| Net Cash Provided by Operating Activities | $-56.19M | $-32.61M | $-40.60M | $-42.88M | $-18.62M |
| Investments in Property Plant and Equipment | $-254.00K | $-769.00K | $-3.61M | $-498.00K | $-560.00K |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-254.00K | $-769.00K | $-3.61M | $-498.00K | $-560.00K |
| Debt Repayment | $-10.00M | $40.00M | $- | $- | $- |
| Common Stock Issued | $23.58M | $18.33M | $15.74M | $111.60M | $94.01M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-496.00K | $100.00K | $166.00K | $-2.17M | $94.02M |
| Net Cash Used Provided by Financing Activities | $13.08M | $58.43M | $15.91M | $109.43M | $93.86M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-43.36M | $25.05M | $-28.30M | $66.05M | $74.67M |
| Cash at End of Period | $112.22M | $155.58M | $130.53M | $158.83M | $92.78M |
| Cash at Beginning of Period | $155.58M | $130.53M | $158.83M | $92.78M | $18.10M |
| Operating Cash Flow | $-56.19M | $-32.61M | $-40.60M | $-42.88M | $-18.62M |
| Capital Expenditure | $-254.00K | $-769.00K | $-3.61M | $-498.00K | $-560.00K |
| Free Cash Flow | $-56.44M | $-33.38M | $-44.21M | $-43.37M | $-19.18M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-20.40M | $-16.67M | $-17.25M | $-16.19M | $-12.00M | $-8.29M | $-5.10M | $-11.98M | $-11.93M | $-11.94M | $-14.59M | $-15.34M | $-17.87M | $-13.76M | $-10.92M | $-7.43M | $-7.40M | $-6.07M | $2.26M | $-3.83M |
| Depreciation and Amortization | $442.00K | $454.00K | $454.00K | $464.00K | $460.00K | $445.00K | $434.00K | $425.00K | $417.00K | $404.00K | $185.00K | $98.00K | $48.00K | $67.00K | $62.00K | $39.00K | $44.00K | $41.00K | $42.00K | $23.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-2.81M | $-3.11M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-7.30M | $- |
| Stock Based Compensation | $1.91M | $2.01M | $2.60M | $2.31M | $1.87M | $2.10M | $1.93M | $2.11M | $1.94M | $1.94M | $1.78M | $1.75M | $1.30M | $1.48M | $781.00K | $539.00K | $221.00K | $133.00K | $221.00K | $57.00K |
| Change in Working Capital | $3.05M | $1.75M | $589.00K | $-2.34M | $4.63M | $-2.09M | $-8.60M | $163.00K | $-2.95M | $-5.16M | $11.49M | $-834.00K | $3.84M | $-377.00K | $-552.00K | $-635.00K | $809.00K | $973.00K | $330.00K | $196.00K |
| Accounts Receivables | $464.00K | $81.00K | $230.00K | $575.00K | $4.56M | $1.02M | $-672.00K | $673.00K | $-2.63M | $-2.08M | $-2.22M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $5.34M | $- | $672.00K | $- | $2.63M | $2.08M | $2.22M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $2.59M | $849.00K | $2.48M | $-2.47M | $-4.58M | $-104.00K | $-616.00K | $903.00K | $-105.00K | $-910.00K | $806.00K | $-674.00K | $651.00K | $-1.51M | $1.14M | $724.00K | $-540.00K | $350.00K | $276.00K | $302.00K |
| Other Working Capital | $-6.00K | $822.00K | $-2.12M | $-447.00K | $-693.00K | $-3.00M | $-7.98M | $-1.41M | $-2.85M | $-4.25M | $10.68M | $-160.00K | $3.19M | $1.13M | $-1.69M | $-1.36M | $1.35M | $623.00K | $54.00K | $-106.00K |
| Other Non Cash Items | $749.00K | $-6.00K | $223.00K | $5.59M | $3.26M | $3.74M | $409.00K | $-612.00K | $653.00K | $295.00K | $840.00K | $383.00K | $11.00K | $172.00K | $170.00K | $166.00K | $319.00K | $350.00K | $156.00K | $152.00K |
| Net Cash Provided by Operating Activities | $-14.25M | $-12.46M | $-14.18M | $-15.30M | $-4.58M | $-7.21M | $-10.92M | $-9.90M | $-11.87M | $-14.47M | $-303.00K | $-13.95M | $-12.67M | $-12.42M | $-10.46M | $-7.33M | $-6.01M | $-4.92M | $-4.29M | $-3.40M |
| Investments in Property Plant and Equipment | $-123.00K | $-3.00K | $-17.00K | $-111.00K | $-198.00K | $-221.00K | $-182.00K | $-168.00K | $-518.00K | $-1.95M | $-1.11M | $-28.00K | $-272.00K | $-102.00K | $-111.00K | $-13.00K | $-9.00K | $-57.00K | $-45.00K | $-449.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-123.00K | $-3.00K | $-17.00K | $-111.00K | $-198.00K | $-221.00K | $-182.00K | $-168.00K | $-518.00K | $-1.95M | $-1.11M | $-28.00K | $-272.00K | $-102.00K | $-111.00K | $-13.00K | $-9.00K | $-57.00K | $-45.00K | $-449.00K |
| Debt Repayment | $- | $- | $-10.00M | $- | $- | $- | $- | $40.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $2.48M | $-29.00K | $877.00K | $20.25M | $8.88M | $182.00K | $642.00K | $8.62M | $1.43M | $11.11M | $3.65M | $159.00K | $111.60M | $-276.00K | $109.64M | $21.00K | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $66.00K | $23.00K | $-597.00K | $12.00K | $191.00K | $-141.00K | $50.00K | $- | $-174.00K | $-32.00K | $-238.00K | $159.00K | $38.00K | $-276.00K | $110.20M | $-538.00K | $71.88M | $-97.00K | $22.07M | $- |
| Net Cash Used Provided by Financing Activities | $2.55M | $-6.00K | $-9.72M | $20.26M | $9.07M | $41.00K | $692.00K | $48.62M | $1.26M | $11.08M | $3.42M | $159.00K | $38.00K | $-276.00K | $110.20M | $-538.00K | $71.88M | $-97.00K | $22.07M | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-215.00K | $204.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-11.83M | $-12.47M | $-3.89M | $4.85M | $4.08M | $-7.18M | $-10.41M | $38.56M | $-11.13M | $-5.35M | $2.00M | $-13.82M | $-12.91M | $-12.79M | $99.63M | $-7.88M | $65.86M | $-5.08M | $17.73M | $-3.85M |
| Cash at End of Period | $112.22M | $124.04M | $135.30M | $139.19M | $134.34M | $130.27M | $158.68M | $169.09M | $130.53M | $141.66M | $147.01M | $145.01M | $158.83M | $171.74M | $184.53M | $84.90M | $92.78M | $26.91M | $31.99M | $14.26M |
| Cash at Beginning of Period | $124.04M | $136.51M | $139.19M | $134.34M | $130.27M | $137.45M | $169.09M | $130.53M | $141.66M | $147.01M | $145.01M | $158.83M | $171.74M | $184.53M | $84.90M | $92.78M | $26.91M | $31.99M | $14.26M | $18.10M |
| Operating Cash Flow | $-14.25M | $-12.46M | $-14.18M | $-15.30M | $-4.58M | $-7.21M | $-10.92M | $-9.90M | $-11.87M | $-14.47M | $-303.00K | $-13.95M | $-12.67M | $-12.42M | $-10.46M | $-7.33M | $-6.01M | $-4.92M | $-4.29M | $-3.40M |
| Capital Expenditure | $-123.00K | $-3.00K | $-17.00K | $-111.00K | $-198.00K | $-221.00K | $-182.00K | $-168.00K | $-518.00K | $-1.95M | $-1.11M | $-28.00K | $-272.00K | $-102.00K | $-111.00K | $-13.00K | $-9.00K | $-57.00K | $-45.00K | $-449.00K |
| Free Cash Flow | $-14.38M | $-12.46M | $-14.19M | $-15.41M | $-4.78M | $-7.43M | $-11.10M | $-10.07M | $-12.39M | $-16.43M | $-1.41M | $-13.98M | $-12.95M | $-12.52M | $-10.57M | $-7.34M | $-6.02M | $-4.98M | $-4.34M | $-3.85M |
Werewolf Therapeutics Dividends
Explore Werewolf Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Werewolf Therapeutics News
Read the latest news about Werewolf Therapeutics, including recent articles, headlines, and updates.
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J.
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half and the second half of 2025, respectively –
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J.
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and immunological diseases, today announced the appointment of Anil Singhal, Ph.D., President and Chief Executive Officer of Trishula Therapeutics, as a member of its board of directors.
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 12:55 pm ET on Thursday, December 5, 2024, at the 7th Annual Evercore ISI HealthCONx Healthcare Conference, taking place December 3-5 in Miami, Florida.
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals -
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical data for rhIL-12 -
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy -
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 1:00 PM ET on June 6 at the Jefferies Global Healthcare Conference, taking place June 4-6, 2024, in New York City, New York.
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers -
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
First Data Demonstrating Application of PREDATOR™ Platform in Immune-Mediated Diseases WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced a poster presenting preclinical data characterizing conditionally-activated IL-10 INDUKINE molecules for the treatment of colitis in animal models, a novel approach leveraging its PREDATOR™ protein engineering platform, at IMMUNOLOGYTM 2024, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Chicago, Illinois.
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
WTX-518, a conditionally activated IL-18 INDUKINE TM molecule that resists suppression by IL-18BP, led to complete tumor regressions in preclinical models
Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to Gilead, but I wouldn't be surprised if Werewolf Therapeutics also has a competitive modified IL-12, with WTX-330. Werewolf Therapeutics is reporting data from its clinical trials of WTX-124 and WTX-330 this half (H1'24), providing near-term catalysts.
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel disease PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel disease
How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
The consensus price target hints at a 92.4% upside potential for Werewolf Therapeutics, Inc. (HOWL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 9:20 AM ET on March 13, 2024, at the Leerink Partners Global Biopharma Conference, taking place March 11-13, 2024, in Miami, Florida.
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.
Werewolf Therapeutics: Still In The Race To Develop Next Generation Cytokines
HOWL reported interim data in November from its phase 1/1b trial of WTX-124 in solid tumors. There are signs of antitumor activity at the 12 mg dose of WTX-124, with two unconfirmed partial responses seen. HOWL has room to impress further, with additional data expected in H1'24. With the company testing a higher 18 mg dose, the potential for improvement on existing activity exists.
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 8:20 AM ET on November 29 at the Evercore ISI HealthCONx Conference, taking place November 28-30, 2023, in Miami, Florida.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for HOWL.